Evaxion files 6-K with Q3 2025 update release

Evaxion A/S, a Denmark-based clinical-stage TechBio company developing AI-Immunology™ powered vaccines, has filed a Form 6-K for November 2025.

Accepted by SEC EDGAR 11/06/2025 - 07:45 AM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Evaxion A/S, a Denmark-based clinical-stage TechBio company developing AI-Immunology™ powered vaccines, has filed a Form 6-K for November 2025. The filing furnishes a press release titled “Evaxion announces business update and third quarter 2025 financial results” as Exhibit 99.1 and incorporates this report by reference into multiple existing registration statements on Forms S-8, F-3, and F-1.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Evaxion A/S (EVAX) report in this November 2025 Form 6-K?

Evaxion A/S files a Form 6-K that furnishes a press release providing a business update and third quarter 2025 financial results. The filing also incorporates this report by reference into several existing registration statements on Forms S-8, F-3, and F-1.

Which press release is attached to Evaxion A/S (EVAX) November 2025 Form 6-K?

The Form 6-K attaches a press release titled “Evaxion announces business update and third quarter 2025 financial results” as Exhibit 99.1. This exhibit contains the detailed business update and financial information for the third quarter of 2025.

How is this Evaxion A/S (EVAX) Form 6-K used in the company’s registration statements?

The report on Form 6-K is deemed incorporated by reference into Evaxion A/S’s registration statements on Form S-8 and multiple Forms F-3 and F-1. This means the information in the 6-K becomes legally part of those registration statements from the filing date.

What type of company is Evaxion A/S (EVAX) according to this Form 6-K?

Evaxion A/S is described as a clinical-stage TechBio company focused on developing AI-Immunology™ powered vaccines. This highlights its combination of technology and biotechnology approaches to create vaccine candidates using artificial intelligence–driven immunology platforms.

Who signed the Evaxion A/S (EVAX) November 2025 Form 6-K?

The Form 6-K was signed on behalf of Evaxion A/S by Birgitte Rønø, who is identified as the Interim Chief Executive Officer. The signature date listed in the document is November 6, 2025, confirming official authorization of the filing.

Does Evaxion A/S (EVAX) file annual reports on Form 20-F or Form 40-F?

The Form 6-K indicates that Evaxion A/S files annual reports under cover of Form 20-F, not Form 40-F. This reflects its status as a foreign private issuer that reports to the U.S. Securities and Exchange Commission using the 20-F framework.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2025

Commission File Number: 001-39950

Evaxion A/S
(Exact Name of Registrant as Specified in Its Charter)

Dr. Neergaards Vej 5f
DK-2970 Hoersholm
Denmark
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F [ X ]      Form 40-F [   ]

INCORPORATION BY REFERENCE

This report on Form 6-K shall be deemed to be incorporated by reference in Evaxion A/S’s registration statements on Form S-8 (File No. 333-255064), on Form F-3 (File No. 333-265132), on Form F-1, as amended (File No. 333-266050), Form F-1 (File No. 333-276505), Form F-1 (File No. 333-279153), Form F-1 (File No. 333-283304), and Form F-3 (File No. 333- 285778), including any prospectuses forming a part of such registration statements and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

Press Release

On November 6, 2025, Evaxion A/S (the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, issued a press release titled "Evaxion announces business update and third quarter 2025 financial results". A copy of the press release is furnished as Exhibit 99.1 to this report on Form 6-K.

Exhibits 

Exhibit No.		Description
99.1		Evaxion announces business update and third quarter 2025 financial results

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

			Evaxion A/S
			(Registrant)
Date: November 6, 2025		By:	/s/ Birgitte Rønø
			Birgitte Rønø
			Interim Chief Executive Officer